Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Docetaxel × Clear all

NCT06618014 2026-05-15

NeoTOP

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05645380 2026-04-28

NeoTRACT

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07017673 2026-04-02

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04947189 2025-05-15

4CAST

Phase 1/2 Recruiting

Triple Negative Breast Neoplasms

NCT02547987 2025-03-12

CADENCE

Phase 2 Active not recruiting

25 enrolled 9 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06795503 2025-01-28

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Unknown

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02834403 2023-12-15

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Phase 1/2 Completed

37 enrolled 20 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02124902 2022-11-07

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Phase 2 Terminated

148 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT03154749 2022-09-01

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT02413320 2021-05-10

NeoSTOP

Phase 2 Completed

101 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01216111 2020-05-19

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

Phase 3 Completed

Triple Negative Breast Neoplasms

NCT01642771 2017-04-19

Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT01208480 2012-04-10

Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms